Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including Mounjaro (for diabetes) and Zepbound (for weight loss). Together, those two products generated $5.4 billion in sales for Eli Lilly last quarter, or 40% of the top line.
Eli Lilly & Co. stock underperforms Friday when compared to competitors
Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,114.63 and Dow Jones Industrial Average DJIA falling 0.
The reason is simple: our research has shown that we can outperform the market by imitating the top stock ... transfer to locally manufacture the insulin. This initiative is part of Eli Lilly ...
See the 10 stocks » Below, I'm going to dive into what caused Lilly's stock to drop earlier this week and assess if the current price action is a good opportunity to buy the dip. What caused Eli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback